SARMs
Evidence: animal_plus_anecdotal
SR-9009 is a synthetic agonist of REV-ERBa and REV-ERBb, nuclear receptors that form the repressive limb of the circadian clock and regulate metabolic gene expression. REV-ERB activation represses BMAL1/CLOCK transcription, modulating circadian rhythm. In skeletal muscle, SR-9009 increases mitochondrial count and oxidative capacity by upregulating mitochondrial biogenesis genes. It enhances fatty acid and glucose oxidation, increases exercise endurance, and reduces lipogenesis in the liver. SR-9009 also reduces inflammatory gene expression via NF-kB pathway suppression. Recent research has identified significant REV-ERB-independent effects, suggesting the mechanism is more complex than initially characterized.
Standard: Research indicates 20-30 mg daily orally, split into 3-4 doses due to very short half-life (~4 hours). Some users prefer sublingual administration for improved bioavailability.
Maintenance: Research indicates 10-20 mg daily, split into 3-4 evenly spaced doses.
Administration: oralsublingual
Timing: Split into 3-4 doses throughout the day due to ~4-hour half-life. Example: 7am, 11am, 3pm, 7pm. Avoid late-night dosing as REV-ERB modulation may affect circadian rhythm and sleep.
Duration: 8-12 week cycles. No HPG suppression. Cycling recommended due to limited long-term data.
SR-9009's major limitation is extremely poor oral bioavailability (~2-3% in animal studies), which raises fundamental questions about whether the effects reported by oral users are pharmacologically mediated or placebo. The original Solt et al. (2012) study in Nature used IP injection, not oral dosing. A 2019 PNAS study found that many of SR-9009's anti-proliferative effects are REV-ERB-independent, complicating the mechanistic picture. SR-9009 does not suppress the HPG axis or testosterone — it is not a SARM by mechanism (does not bind the androgen receptor). No PCT required. Required bloodwork: CMP, CBC, lipid panel, fasting glucose at baseline and every 4-6 weeks. Sleep quality monitoring (subjective tracking and/or wearable data). Liver function panel. The bioavailability issue means standard oral dosing may be largely ineffective. Medical supervision recommended.
Not FDA-approved. Research chemical only with no human clinical trials. Significant bioavailability concern — oral bioavailability estimated at only ~2-3% in animal models, questioning whether oral dosing achieves therapeutic tissue levels in humans. Sublingual or injectable formulations may partially address this. Source with third-party COA.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →